Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

NZ sharemarket rocked by US inflation data
Markets Market close

NZ sharemarket rocked by US inflation data

The S&P/NZX 50 Index closed at 141.34 points or 1.18%.

Duncan Bridgeman 26 Apr 2024
Australian company seeks A$30m for Otago gold mining
Markets

Australian company seeks A$30m for Otago gold mining

Santana Minerals wants to 'rapidly advance' a South Island gold mining project.

John Anthony 26 Apr 2024
NZ sharemarket celebrates highest single-day rise in over five months
Markets Market close

NZ sharemarket celebrates highest single-day rise in over five months

The S&P/NZX 50 Index closed at 11,946.43, increasing 143.15 points or 1.21%.

Graham Skellern 24 Apr 2024
'Serious compliance breaches' in NZ sharemarket
Markets

'Serious compliance breaches' in NZ sharemarket

Seven matters were referred to the NZ Markets Disciplinary Tribunal last year.

Murray Jones 24 Apr 2024